Farrukh Shah
Research Subjects
Farrukh Shah has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
- Ali T. Taher
Division of Hematology‐Oncology, Department of Internal Medicine American University of Beirut Beirut Lebanon
4 shared publications - Maria Domenica Cappellini
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, SC Medicina ad Indirizzo Metabolico Milan Italy
4 shared publications - Khaled M. Musallam
Center for Research on Rare Blood Disorders and Thalassemia & Sickle Cell Center, Burjeel Cancer Institute, Burjeel Medical City, Abu Dhabi 92510, United Arab Emirates; Department of Public Health & Epidemiology, Khalifa University, Abu Dhabi, United Arab Emirates; Division of Hematology/Oncology, Department of Pediatrics, Weill Cornell Medicine, New York, NY, USA
3 shared publications - Sujit Sheth
Division of Hematology/Oncology, Department of Pediatrics, Weill Cornell Medicine, New York, NY, USA
3 shared publications - Aylin Yucel
Bristol Myers Squibb, Princeton, New Jersey, USA
2 shared publications - Emma Schiller
Evidera, Waltham, MA 02451, USA
2 shared publications
Latest Publications
- 6 October 2026
- Published by Elsevier in The Lancet Haematology
- Vol. 13 (11) , e834-e848
The expanding therapeutic landscape of β-thalassaemia
- 6 October 2026
- Published by Elsevier in The Lancet Haematology
- Vol. 13 (11) , e834-e848
The expanding therapeutic landscape of β-thalassaemia
- 28 August 2026
- Published by Elsevier in Blood Reviews
Non-transfusion-dependent β-thalassemia: A disease of clinical paradoxes
- 28 August 2026
- Published by Elsevier in Blood Reviews
Non-transfusion-dependent β-thalassemia: A disease of clinical paradoxes
- Top Cited Papers
- 1 January 2026
- Published by Elsevier in The Lancet Haematology
- Vol. 13 (1) , e49-e54
Management of transfusion-dependent β-thalassaemia in the era of novel therapies: a prioritisation-based matrix for settings with limited resources
- 1 January 2026
- Published by Elsevier in The Lancet Haematology
- Vol. 13 (1) , e49-e54
Top Cited PapersManagement of transfusion-dependent β-thalassaemia in the era of novel therapies: a prioritisation-based matrix for settings with limited resources
- 7 May 2024
- Published by Wiley in British Journal of Haematology
- Vol. 204 (6) , 2194-2209
Guideline for the Management of Conception and Pregnancy in Thalassaemia Syndromes: A British Society for Haematology Guideline
Summary: This comprehensive guideline, developed by a representative group of UK‐based medical experts specialising in haemoglobinopathies, addresses the management of conception and pregnancy in patients with thalassaemia. A systematic search of PubMed and EMBASE using specific keywords, formed the basis of the literature review. Key terms included “thalassaemia,” “pregnancy,” “Cooley's anaemia,” “Mediterranean anaemia,” and others, covering aspects such as fertility, iron burden and ultrasonography. The guideline underwent rigorous review by prominent organisations, including the Endocrine Society, the Royal College of Obstetricians and Gynaecologists (RCOG), the United Kingdom Thalassaemia Society and the British Society of Haematology (BSH) guideline writing group. Additional feedback was solicited from a sounding board of UK haematologists, ensuring a thorough and collaborative approach. The objective of the guideline is to equip healthcare professionals with precise recommendations for managing conception and pregnancy in patients with thalassaemia.
- 7 May 2024
- Published by Wiley in British Journal of Haematology
- Vol. 204 (6) , 2194-2209
Guideline for the Management of Conception and Pregnancy in Thalassaemia Syndromes: A British Society for Haematology Guideline
Summary: This comprehensive guideline, developed by a representative group of UK‐based medical experts specialising in haemoglobinopathies, addresses the management of conception and pregnancy in patients with thalassaemia. A systematic search of PubMed and EMBASE using specific keywords, formed the basis of the literature review. Key terms included “thalassaemia,” “pregnancy,” “Cooley's anaemia,” “Mediterranean anaemia,” and others, covering aspects such as fertility, iron burden and ultrasonography. The guideline underwent rigorous review by prominent organisations, including the Endocrine Society, the Royal College of Obstetricians and Gynaecologists (RCOG), the United Kingdom Thalassaemia Society and the British Society of Haematology (BSH) guideline writing group. Additional feedback was solicited from a sounding board of UK haematologists, ensuring a thorough and collaborative approach. The objective of the guideline is to equip healthcare professionals with precise recommendations for managing conception and pregnancy in patients with thalassaemia.
- 10 June 2023
- Published by Elsevier in Value in Health
- Vol. 26 (6) , S156
EE528 Healthcare Resource Utilization Among Patients with Sickle Cell Disease with Recurrent Vaso-Occlusive Crises in England
- 10 June 2023
- Published by Elsevier in Value in Health
- Vol. 26 (6) , S156
EE528 Healthcare Resource Utilization Among Patients with Sickle Cell Disease with Recurrent Vaso-Occlusive Crises in England
- Open Access
- 22 December 2022
- Published by Elsevier in Blood Reviews
- Vol. 59, 101039
Erythropoiesis in lower-risk myelodysplastic syndromes and beta-thalassemia
- 22 December 2022
- Published by Elsevier in Blood Reviews
- Vol. 59, 101039
Open AccessErythropoiesis in lower-risk myelodysplastic syndromes and beta-thalassemia
- Open Access
- 30 July 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (15) , 4448
Relationship between Serum Ferritin and Outcomes in β-Thalassemia: A Systematic Literature Review
Among the difficulties of living with β-thalassemia, patients frequently require blood transfusions and experience iron overload. As serum ferritin (SF) provides an indication of potential iron overload, we conducted a systematic literature review (SLR) to assess whether SF levels are associated with clinical and economic burden and patient-reported outcomes (PROs). The SLR was conducted on 23 April 2020 and followed by analysis of the literature. Dual-screening was performed at the title, abstract, and full-text levels using predefined inclusion and exclusion criteria. Ten studies identified by the SLR were eligible for inclusion in the analysis. Seven studies were conducted in Europe, and most were prospective or retrospective in design. The patient populations had a median age of 20.7–42.6 years, with a percentage of men of 38–80%. Sparse data were found on the correlation between SF levels and mortality, and hepatic, skeletal, and cardiac complications; however, in general, higher SF levels were associated with worsened outcomes. The bulk of the evidence reported on the significant association between higher SF levels and endocrine dysfunction in its many presentations, including a 14-fold increase in the risk of diabetes for patients with persistently elevated SF levels. No studies reporting data on PROs or economic burden were identified by the SLR. SF levels provide another option for prognostic assessment to predict a range of clinical outcomes in patients with β-thalassemia.
- 30 July 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (15) , 4448
Open AccessRelationship between Serum Ferritin and Outcomes in β-Thalassemia: A Systematic Literature Review
Among the difficulties of living with β-thalassemia, patients frequently require blood transfusions and experience iron overload. As serum ferritin (SF) provides an indication of potential iron overload, we conducted a systematic literature review (SLR) to assess whether SF levels are associated with clinical and economic burden and patient-reported outcomes (PROs). The SLR was conducted on 23 April 2020 and followed by analysis of the literature. Dual-screening was performed at the title, abstract, and full-text levels using predefined inclusion and exclusion criteria. Ten studies identified by the SLR were eligible for inclusion in the analysis. Seven studies were conducted in Europe, and most were prospective or retrospective in design. The patient populations had a median age of 20.7–42.6 years, with a percentage of men of 38–80%. Sparse data were found on the correlation between SF levels and mortality, and hepatic, skeletal, and cardiac complications; however, in general, higher SF levels were associated with worsened outcomes. The bulk of the evidence reported on the significant association between higher SF levels and endocrine dysfunction in its many presentations, including a 14-fold increase in the risk of diabetes for patients with persistently elevated SF levels. No studies reporting data on PROs or economic burden were identified by the SLR. SF levels provide another option for prognostic assessment to predict a range of clinical outcomes in patients with β-thalassemia.
- Open Access
- 1 June 2022
- Published by Taylor & Francis in Patient Preference and Adherence
- Vol. ume 16, 1423-1437
Promoting Adherence to Iron Chelation Treatment in Beta-Thalassemia Patients
Thalassaemia is one of the commonest inherited genetic disorders world-wide with around 25,000 births of the most severely affected transfusion dependent children annually. Patients with transfusion dependent thalassaemia require regular blood transfusions to maintain life but because of this will develop iron overload. To remove the excess iron, patients are required to take iron chelation therapy (ICT). ICT requires lifelong adherence to treatment to prevent end organ damage from developing. Many of these preventable complications make adherence to therapy more complex for patients. In this review, we focus on two commonly encountered patient scenarios and discuss how different psychological models and a relational theory can be used to understand and support adherence to treatment.
- 1 June 2022
- Published by Taylor & Francis in Patient Preference and Adherence
- Vol. ume 16, 1423-1437
Open AccessPromoting Adherence to Iron Chelation Treatment in Beta-Thalassemia Patients
Thalassaemia is one of the commonest inherited genetic disorders world-wide with around 25,000 births of the most severely affected transfusion dependent children annually. Patients with transfusion dependent thalassaemia require regular blood transfusions to maintain life but because of this will develop iron overload. To remove the excess iron, patients are required to take iron chelation therapy (ICT). ICT requires lifelong adherence to treatment to prevent end organ damage from developing. Many of these preventable complications make adherence to therapy more complex for patients. In this review, we focus on two commonly encountered patient scenarios and discuss how different psychological models and a relational theory can be used to understand and support adherence to treatment.
- Open Access
- 8 February 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (3) , 895
A Systematic Literature Review of the Relationship between Serum Ferritin and Outcomes in Myelodysplastic Syndromes
Anemia is the most common form of cytopenia in patients with myelodysplastic syndromes (MDS), who require chronic red blood cell transfusions and may present high serum ferritin (SF) levels as a result of iron overload. To better understand the potential effects of high SF levels, we conducted a systematic literature review (SLR) to identify evidence on the relationship between SF levels and clinical, economic, or humanistic outcomes in adult patients with MDS. Of 267 references identified, 21 were included. No studies assessing SF levels and their relationship with humanistic or economic outcomes were identified. Increased SF levels were an indicator of worse overall survival and other worsened outcomes; however, the association was not consistently significant. SF levels were a significant prognostic factor for relapse incidence of MDS and showed a significant positive correlation with number of blood units transfused but were not associated with progression to acute myeloid leukemia or the time to transformation. Higher SF levels were also an indicator of a lower likelihood of leukemia-free survival, relapse-free survival, and event-free survival. The SLR suggests that SF levels are associated with clinical outcomes in MDS, with higher levels correlated with number of blood units transfused, frequently indicating worse outcomes.
- 8 February 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (3) , 895
Open AccessA Systematic Literature Review of the Relationship between Serum Ferritin and Outcomes in Myelodysplastic Syndromes
Anemia is the most common form of cytopenia in patients with myelodysplastic syndromes (MDS), who require chronic red blood cell transfusions and may present high serum ferritin (SF) levels as a result of iron overload. To better understand the potential effects of high SF levels, we conducted a systematic literature review (SLR) to identify evidence on the relationship between SF levels and clinical, economic, or humanistic outcomes in adult patients with MDS. Of 267 references identified, 21 were included. No studies assessing SF levels and their relationship with humanistic or economic outcomes were identified. Increased SF levels were an indicator of worse overall survival and other worsened outcomes; however, the association was not consistently significant. SF levels were a significant prognostic factor for relapse incidence of MDS and showed a significant positive correlation with number of blood units transfused but were not associated with progression to acute myeloid leukemia or the time to transformation. Higher SF levels were also an indicator of a lower likelihood of leukemia-free survival, relapse-free survival, and event-free survival. The SLR suggests that SF levels are associated with clinical outcomes in MDS, with higher levels correlated with number of blood units transfused, frequently indicating worse outcomes.
- Open Access
- 6 October 2021
- Published by Wiley in British Journal of Haematology
- Vol. 196 (2) , 336-350
Guidelines for the monitoring and management of iron overload in patients with haemoglobinopathies and rare anaemias
- 6 October 2021
- Published by Wiley in British Journal of Haematology
- Vol. 196 (2) , 336-350
Open AccessGuidelines for the monitoring and management of iron overload in patients with haemoglobinopathies and rare anaemias